Current challenges and future directions in the management of ovarian cancer: Proceedings of the first global workshop on ovarian cancer

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Ovarian Cancer

• Publication date

  2010-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3816/COC.2010.N.015
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer.

  2016cited by this paper
• Pharmaceutical Management of Ovarian Cancer

  2012cited by this paper
• The use of hormonal contraception and its protective role against endometrial and ovarian cancer.

  2010cited by this paper
• First-line treatment of advanced ovarian cancer: current research and perspectives

  2010cited by this paper
• A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA).

  2010cited by this paper
• Development of a multimarker assay for early detection of ovarian cancer.

  2010cited by this paper
• Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

  2010cited by this paper
• Diet and survival after ovarian cancer: where are we and what's next?

  2010cited by this paper
• Ovarian cancer symptoms speak out--but what are they really saying?

  2010cited by this paper
• Predictive value of symptoms for early detection of ovarian cancer.

  2010cited by this paper
• The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer

  2010cited by this paper
• Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

  2010cited by this paper
• Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

  2010cited by this paper
• Current state of biomarker development for clinical application in epithelial ovarian cancer.

  2010cited by this paper
• Prediagnosis food patterns are associated with length of survival from epithelial ovarian cancer.

  2010cited by this paper
• Unmasking the complexities of mucinous ovarian carcinoma.

  2010cited by this paper
• Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study.

  2010cited by this paper
• Ovarian Cancer Screening and Early Detection

  2009cited by this paper
• Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: From Platinum Doublets to Nonplatinum Doublets and Adding Antiangiogenesis Compounds

  2009cited by this paper
• Antiangiogenic drugs in ovarian cancer

  2009cited by this paper
• The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.

  2009cited by this paper
• mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary

  2009cited by this paper
• Body mass index and risk of ovarian cancer

  2009cited by this paper
• A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG).

  2009cited by this paper
• Beyond chemotherapy: targeted therapies in ovarian cancer

  2009cited by this paper
• Prospective study of physical activity and the risk of ovarian cancer

  2009cited by this paper
• Proteomic Profiling in Ovarian Cancer

  2009cited by this paper
• Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

  2009cited by this paper
• Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study

  2009cited by this paper
• Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.

  2009cited by this paper
• What do patients think about CA-125 monitoring in the follow-up? Results from a multicenter trial in 1,060 patients with ovarian cancer.

  2009cited by this paper
• Ovarian cancer update: lessons from morphology, molecules, and mice.

  2009cited by this paper
• Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy.

  2009cited by this paper
• Risk of ovarian cancer in women with symptoms in primary care: population based case-control study

  2009cited by this paper
• Prediagnostic symptoms of ovarian carcinoma: a case-control study.

  2009cited by this paper
• A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials).

  2009cited by this paper
• Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

  2009cited by this paper
• Timing of debulking surgery in advanced ovarian cancer

  2008cited by this paper
• AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

  2008cited by this paper
• EORTC-GcG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA)

  2008cited by this paper
• The clinical-pathologic factors relevant to intraperitoneal chemotherapy in ovarian cancer: An analysis of two Gynecologic Oncology Group trials

  2008cited by this paper
• Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.

  2008cited by this paper
• IP catheter complications and associated risk factors in patients with ovarian cancer

  2008cited by this paper
• Diagnostic Markers for Early Detection of Ovarian Cancer

  2008cited by this paper
• A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial

  2008cited by this paper
• Low-grade serous ovarian cancer: a unique disease

  2008cited by this paper
• Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

  2008cited by this paper
• Update on lymphadenectomy in early and advanced ovarian cancer

  2008cited by this paper
• The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13 918 patients

  2007cited by this paper
• Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition.

  2007cited by this paper
• CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib—A trial of the PMH Phase II Consortium

  2007cited by this paper
• Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics

  2007cited by this paper
• Experience with bevacizumab in the management of epithelial ovarian cancer.

  2007cited by this paper
• Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study

  2007cited by this paper
• Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer

  2007cited by this paper
• VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study

  2007cited by this paper
• Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial.

  2007cited by this paper
• Results of all-intraperitoneal carboplatin and paclitaxel regimen shows good tolerability and efficacy for advanced ovarian cancer

  2007cited by this paper
• What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

  2007cited by this paper
• A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer

  2007cited by this paper
• Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).

  2007cited by this paper
• Physical activity and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition.

  2007cited by this paper
• Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.

  2007cited by this paper
• Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

  2007cited by this paper
• Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

  2007cited by this paper
• Role of surgery in ovarian carcinoma.

  2007cited by this paper
• Final results of After-6 protocol 1: A phase III trial of observation versus 6 courses of paclitaxel (Pac) in advanced ovarian cancer patients in complete response (CR) after platinum-paclitaxel chemotherapy (CT)

  2007cited by this paper
• Association of Lymphadenectomy and Survival in Stage I Ovarian Cancer Patients

  2007cited by this paper
• Bevacizumab in the treatment of ovarian cancer

  2007cited by this paper
• Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis

  2006cited by this paper
• Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms

  2006cited by this paper
• Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial

  2006cited by this paper
• Weight, height, and body mass index and risk for ovarian cancer in a cohort study.

  2006cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis

  2006cited by this paper
• Notch3 gene amplification in ovarian cancer.

  2006cited by this paper
• Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer

  2006cited by this paper
• Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinoma

  2006cited by this paper
• Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer.

  2006cited by this paper
• Screening for ovarian cancer in the general population.

  2006cited by this paper
• Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

  2006cited by this paper
• Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

  2006cited by this paper
• Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

  2006cited by this paper
• Oral contraceptives and ovarian cancer: an update 1998-2004.

  2006cited by this paper
• Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer

  2006cited by this paper
• Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.

  2005cited by this paper
• Identification of Overexpression and Amplification of ABCF2 in Clear Cell Ovarian Adenocarcinomas by cDNA Microarray Analyses

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers

  2005cited by this paper
• Physical activity and the risk of ovarian cancer: A case‐control study in Canada

  2005cited by this paper
• The Notch pathway in ovarian carcinomas and adenomas

  2005cited by this paper
• Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.

  2005cited by this paper
• Secondary surgical cytoreduction for advanced ovarian carcinoma.

  2004cited by this paper
• Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits?

  2004cited by this paper
• A case-control study of diet and the risk of ovarian cancer.

  2004cited by this paper
• Cancer Facts & Figures 2004

  2004cited by this paper
• AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

  2004cited by this paper
• Anthropometric variables, physical activity, and incidence of ovarian cancer

  2004cited by this paper
• Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

  2004cited by this paper
• Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.

  2004cited by this paper

• Injectable three-dimensional tumor microenvironments to study mechanobiology in ovarian cancer.

  2022cites this paper
• Exercise Among Women With Ovarian Cancer: A Feasibility and Pre-/Post-Test Exploratory Pilot Study.

  2017cites this paper
• Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

  2013cites this paper
• Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts

  2012cites this paper